title: Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
authors.affiliation: Foundation Medicine, Cambridge, MA, USA.
authors.forename: Norma
authors.initials: N
authors.lastname: Palma
authors.affiliation: Division of Hematology-Oncology, University of Cincinnati Cancer Institute, Cincinnati, OH, USA.
authors.forename: John C
authors.initials: JC
authors.lastname: Morris
authors.affiliation: Foundation Medicine, Cambridge, MA, USA.
authors.forename: Siraj M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: Foundation Medicine, Cambridge, MA, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY, USA.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.
authors.forename: Sumanta Kumar
authors.initials: SK
authors.lastname: Pal
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D005260:Female; D005784:Gene Amplification; D006801:Humans; D007191:Indazoles; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D009154:Mutation; D011743:Pyrimidines / Q000627:therapeutic use*; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics; D013449:Sulfonamides / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3